Abstract
Ten patients with acute myeloid leukaemia on failure or relapse were treated by Amsacrine and high-dose (12 g/m2) Cytosine Arabinosyl (phase II trial). Four patients achieved complete remission, over six months in one instance. Hematologic toxicity was important but extra-hematologic toxicity was mild. These two drugs could be used as induction or reinforcement treatment in acute myeloid leukaemia.
MeSH terms
-
Adult
-
Aminoacridines / administration & dosage*
-
Aminoacridines / adverse effects
-
Amsacrine
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cytarabine / administration & dosage*
-
Cytarabine / adverse effects
-
Drug Evaluation
-
Female
-
Follow-Up Studies
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / pathology
-
Male
-
Middle Aged
Substances
-
Aminoacridines
-
Antineoplastic Agents
-
Amsacrine
-
Cytarabine